Advances in Pancreatic Cancer: Guidance to Improve the Care of Veterans

Download this PDF resource of expert recommendations on the diagnosis, staging, and treatment of advanced pancreatic cancer, including therapy selection and adverse event management.
Format: Adobe Acrobat (.pdf)
File Size: 102 KB
Released: January 30, 2018


This activity is supported by an educational grant from
Celgene Corporation

Related Content

In this downloadable slideset from the CCO Pancreatic Cancer VA meeting series, Thomas H. Cartwright, MD, and Milind Javle, MD, provide expert perspective on optimizing treatment choices for patients with advanced pancreatic cancer.

Released: February 16, 2018

Expert answers to frequently asked questions about modern clinical management of pancreatic cancer, including diagnosis and screening, neoadjuvant treatment, first-line and second-line therapy, and novel approaches such as combining immunotherapy with chemotherapy or radiation.

Tanios Bekaii-Saab, MD, FACP
Program Director
Andrew H. Ko, MD
Program Director
Milind Javle, MD Dan Laheru, MD Kenneth Yu, MD, MSc
Released: January 2, 2018

Oral edoxaban was noninferior to subcutaneous dalteparin regarding combined risk of recurrent VTE or major bleeding in patients with cancer-associated VTE.

Released: December 14, 2017

Compared with dalteparin, rivaroxaban was associated with a lower incidence of VTE recurrence within 6 months but a higher incidence of clinically relevant bleeding events.

Released: December 13, 2017

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?